Fig. 1From: BCG+MMC trial: adding mitomycin C to BCG as adjuvant intravesical therapy for high-risk, non-muscle-invasive bladder cancer: a randomised phase III trial (ANZUP 1301)Pilot data on median (a) I-PSS and (b) cystitis scoresBack to article page